What is Heyde syndrome, including its clinical triad and recommended treatment options?

Heyde Syndrome

Heyde syndrome is a clinical triad consisting of severe aortic stenosis, gastrointestinal bleeding from angiodysplasia, and acquired von Willebrand syndrome type 2A. 1, 2, 3

Clinical Definition and Pathophysiology

The syndrome occurs when high shear stress from a stenotic aortic valve causes proteolytic degradation of high molecular weight von Willebrand factor (vWF) multimers, leading to:

• Loss of platelet-mediated hemostasis (acquired von Willebrand syndrome type 2A)
• Development of gastrointestinal angiodysplasias (tortuous, thin-walled blood vessels in the GI mucosa/submucosa that are prone to rupture)
• Recurrent GI bleeding with chronic anemia requiring blood transfusions 1, 2

The condition predominantly affects elderly patients over 65 years old, with a prevalence of approximately 1.8% among patients undergoing transcatheter aortic valve replacement (TAVR) 4. However, it remains significantly underdiagnosed due to low clinical awareness 1, 5.

Diagnostic Approach

Key Clinical Features to Identify:

• Cardiac: Severe aortic stenosis on echocardiography
• Hematologic: Recurrent anemia requiring blood transfusions, abnormal platelet function assay indicating vWF deficiency
• Gastrointestinal: Dark tarry stools (melena), abdominal cramping, occult or overt GI bleeding 3

Diagnostic Testing Algorithm:

1. Echocardiography to confirm severe aortic stenosis
2. Platelet function assay to detect acquired von Willebrand syndrome
3. Endoscopic evaluation:
   • Capsule endoscopy and double balloon enteroscopy are superior to standard colonoscopy and esophagogastroduodenoscopy for identifying bleeding sources (p<0.01) 5
   • The small intestine, particularly the jejunum, is the most common bleeding location 5
   • Standard upper and lower endoscopy may be negative despite active disease 3

Common diagnostic pitfall: The average time from symptom onset to diagnosis is 23.8 months 5, often because standard endoscopy misses small bowel angiodysplasias. Maintain high clinical suspicion in elderly patients with unexplained recurrent anemia and known aortic stenosis.

Treatment Recommendations

Definitive Treatment:

Aortic valve replacement (surgical or transcatheter) is the definitive treatment that addresses the underlying pathophysiology and prevents rebleeding (p<0.0001 for superiority over non-AVR modalities) 5. Both surgical AVR and TAVR are effective, with TAVR being preferred in elderly patients with multiple comorbidities 1, 3.

Critical Post-TAVR Consideration:

• Residual paravalvular leakage (PVL) ≥ mild grade is associated with recurrent GI bleeding after TAVR (73.3% vs 38.1% without PVL, p=0.05) 4
• Ensure minimal residual PVL during valve implantation to reduce rebleeding risk
• 39.8% of Heyde patients experience recurrent GI bleeding one year after TAVR compared to 21.2% of non-Heyde GI bleeders (p=0.03) 4

Bridging and Adjunctive Therapies:

For patients awaiting valve replacement or who decline surgery:

• Argon plasma coagulation for endoscopic treatment of identified angiodysplasias 2
• Blood transfusions as needed for symptomatic anemia 3, 4
• Octreotide (somatostatin analog) may reduce bleeding, though evidence is limited and some patients are resistant 6
• Beta-blockers (e.g., nadolol) in select cases, particularly when hypertrophic obstructive cardiomyopathy is present 7

Treatment Algorithm:

1. Confirm diagnosis with echocardiography, platelet function assay, and capsule endoscopy/double balloon enteroscopy
2. Stabilize with blood transfusions and endoscopic hemostasis (argon plasma coagulation) if active bleeding
3. Proceed to aortic valve replacement (TAVR preferred in elderly/high-risk patients)
4. Minimize residual PVL during valve implantation
5. Monitor for recurrent bleeding post-procedure, especially if residual PVL present

Important Caveats:

• Only 27 of 77 cases in systematic review provided laboratory evidence for acquired von Willebrand syndrome 5, suggesting the diagnosis should not be excluded based solely on negative vWF testing
• Hypertrophic obstructive cardiomyopathy can also cause Heyde syndrome through similar shear stress mechanisms 7
• Non-AVR modalities (endoscopic therapy alone, medical management) have significantly higher rebleeding rates and should only be used as temporizing measures 5